Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: Focus on epidermal growth factor receptor mutation testing and mutation-positive patientsROENGVORAPHOJ, Monic; TSONGALIS, Gregory J; DRAGNEV, Konstantin H et al.Cancer treatment reviews. 2013, Vol 39, Num 8, pp 839-850, issn 0305-7372, 12 p.Article

Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478ZHI SHI; TIWARI, Amit K; FU, Li-Wu et al.Biochemical pharmacology. 2009, Vol 77, Num 5, pp 781-793, issn 0006-2952, 13 p.Article

Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitorsLI, Dong-Dong; FEI FANG; LI, Jing-Ran et al.Bioorganic & medicinal chemistry letters (Print). 2012, Vol 22, Num 18, pp 5870-5875, issn 0960-894X, 6 p.Article

Significant increase in hEGF uptake is correlated with formation of EGFR dimers induced by the EGFR tyrosine kinase inhibitor gefitinibPENG HE; GANG LI.Cancer chemotherapy and pharmacology. 2013, Vol 72, Num 2, pp 341-348, issn 0344-5704, 8 p.Article

Gefitinib ('Iressa'): a new therapy for advanced non-small-cell lung cancerRECK, Martin; GATZEMEIER, Ulrich.Respiratory medicine. 2005, Vol 99, Num 3, pp 298-307, issn 0954-6111, 10 p.Article

Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activityCHEN, Kuen-Feng; PAO, Kuan-Chuan; SU, Jung-Chen et al.Bioorganic & medicinal chemistry. 2012, Vol 20, Num 20, pp 6144-6153, issn 0968-0896, 10 p.Article

Discovery of novel EGFR tyrosine kinase inhibitors by structure-based virtual screeningSIYUAN LI; XIANQIANG SUN; HONGLI ZHAO et al.Bioorganic & medicinal chemistry letters (Print). 2012, Vol 22, Num 12, pp 4004-4009, issn 0960-894X, 6 p.Article

Epithelial phenotype as a predictive marker for response to EGFR-TKIs in non-small cell lung cancer patients with wild-type EGFRSHENGXIANG REN; CHUNXIA SU; YAYI HE et al.International journal of cancer (Print). 2014, Vol 135, Num 12, pp 2962-2971, issn 0020-7136, 10 p.Article

EGFR Protein Expression in Non-Small Cell Lung Cancer Predicts Response to an EGFR Tyrosine Kinase Inhibitor―A Novel Antibody for Immunohistochemistry or AQUA TechnologyMASCAUX, Celine; WYNES, Murry W; NAGAO, Toshitaka et al.Clinical cancer research (Print). 2011, Vol 17, Num 24, pp 7796-7807, issn 1078-0432, 12 p.Article

Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial DesignCHAFT, Jamie E; OXNARD, Geoffrey R; SIMA, Camelia S et al.Clinical cancer research (Print). 2011, Vol 17, Num 19, pp 6298-6303, issn 1078-0432, 6 p.Article

High EGFR Gene Copy Number and Skin Rash as Predictive Markers for EGFR Tyrosine Kinase Inhibitors in Patients with Advanced Squamous Cell Lung CarcinomaLEE, Youngjoo; HYO SUP SHIM; MOO SUK PARK et al.Clinical cancer research (Print). 2012, Vol 18, Num 6, pp 1760-1768, issn 1078-0432, 9 p.Article

Epithelial Growth Factor Receptor Tyrosine Kinase Inhibitor Prevents Infiltration and Cerebrospinal Fluid Dissemination in Malignant Glioma: An Experimental StudyASANO, Kenichiro; OHKUMA, Hiroki.Neurosurgery. 2011, Vol 69, Num 2, pp 399-410, issn 0148-396X, 12 p.Article

Successful pregnancy with epidermal growth factor receptor tyrosine kinase inhibitor treatment of metastatic lung adenocarcinoma presenting with respiratory failureLEE, Chee-Hong; LIAM, Chong-Kin; PANG, Yong-Kek et al.Lung cancer. 2011, Vol 74, Num 2, pp 349-351, issn 0169-5002, 3 p.Article

Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitorsHYUN SUN WOO; HEE KYUNG AHN; EUN KYUNG CHO et al.Investigational new drugs. 2014, Vol 32, Num 6, pp 1311-1315, issn 0167-6997, 5 p.Article

Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patientsPIRCHER, Andreas; PLONER, Ferdinand; POPPER, Helmut et al.Lung cancer. 2010, Vol 69, Num 3, pp 265-271, issn 0169-5002, 7 p.Article

Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulationSONG, Ji-Young; KIM, Choung-Soo; JENE CHOI et al.Investigational new drugs. 2013, Vol 31, Num 6, pp 1458-1465, issn 0167-6997, 8 p.Article

Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutationsMIN HWAN KIM; HYE RYUN KIM; BYOUNG CHUL CHO et al.Lung cancer. 2014, Vol 84, Num 2, pp 196-202, issn 0169-5002, 7 p.Article

Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinomaWATANABE, Satoshi; SONE, Takashi; WASEDA, Yuko et al.Lung cancer. 2013, Vol 82, Num 2, pp 370-372, issn 0169-5002, 3 p.Article

Crotoxin enhances the antitumor activity of gefinitib (Iressa) in SK-MES-1 human lung squamous carcinoma cellsWANG, Jun-Hua; YAN XIE; WU, Jun-Chao et al.Oncology reports. 2012, Vol 27, Num 5, pp 1341-1347, issn 1021-335X, 7 p.Article

Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinomaLEE, Soo-Chin; LIM, Seng-Gee; SOO, Ross et al.Pharmacogenetics and genomics (Print). 2006, Vol 16, Num 1, pp 73-74, issn 1744-6872, 2 p.Article

A Phase I Trial of Erlotinib and Concurrent Chemoradiotherapy for Stage III and IV (MO) Squamous Cell Carcinoma of the Head and NeckGILBERT, Jill; RUDEK, Michelle A; HIGGINS, Michaela J et al.Clinical cancer research (Print). 2012, Vol 18, Num 6, pp 1735-1742, issn 1078-0432, 8 p.Article

Physicochemical Properties of Epidermal Growth Factor Receptor Inhibitors and Development of a Nanoliposomal Formulation of GefitinibTRUMMER, Brian J; IYER, Vandana; BALU-IYER, Sathy V et al.Journal of pharmaceutical sciences. 2012, Vol 101, Num 8, pp 2763-2776, issn 0022-3549, 14 p.Article

Clinical Outcome According to the Level of Preexisting Epidermal Growth Factor Receptor T790M Mutation in Patients With Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor MutationsYOUNGJOO LEE; GEON KOOK LEE; HEUNG TAE KIM et al.Cancer. 2014, Vol 120, Num 14, pp 2090-2098, issn 0008-543X, 9 p.Article

An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic functionO'BRYANT, Cindy L; HALUSKA, Paul; BELANI, Chandra et al.Cancer chemotherapy and pharmacology. 2012, Vol 69, Num 3, pp 605-612, issn 0344-5704, 8 p.Article

Clinical characteristics of non-small cell lung cancer patients who experienced acquired resistance during gefitinib treatmentKIM, Hye-Ryoun; JAE CHOL LEE; RYU, Jeong-Seon et al.Lung cancer. 2014, Vol 83, Num 2, pp 252-258, issn 0169-5002, 7 p.Article